Mylan said today a second proxy advisory firm is advising its shareholders to support the generic drug maker’s proposed acquisition of over-the-counter drug specialist Perrigo Co.

Mylan said Egan-Jones of Haverford, Pa., is recommending that shareholders vote in favor of Mylan’s proposal to acquire Perrigo when they meet Aug. 28.

In a statement, Mylan said Egan-Jones cited Mylan’s experience in integrating large acquisitions and “the shared culture between Mylan and Perrigo of integrity, respect and responsibility.”

Earlier today, Mylan said Glass Lewis & Co. also recommended that shareholders vote in favor of making an offer for Perrigo. The proxy advisory firm noted "substantial portfolio diversification" and the potential for substantial cuts in operating costs that the acquisition would bring, Mylan said.

Advertise with us

Proxy advisory firms advise pension funds and other institutional investors how to vote their shares.

Mylan shareholders will be asked to OK the acquisition of Dublin, Ireland-based Perrigo at a special meeting set for Aug. 28 in Amsterdam. Mylan, which has its operations base in Cecil, reincorporated in the Netherlands this year.

If shareholders approve the deal, Mylan will then have to sell Perrigo management on a merger that so far has been rejected, or try to win Perrigo's hand by taking the cash and stock offer directly to Perrigo shareholders.

Patricia Sabatini: PSabatini@post-gazette.com or 412-263-3066. Len Boselovic: lboselovic@post-gazette.com or 412-263-1941